aRigen strikes first deal for novel anti-MRSA agent
This article was originally published in Scrip
Green Cross Corp has acquired rights in South Korea to aRigen Pharmaceuticals' lotilibcin (WAP-8294A2), in what is the first licensing deal for the novel anti-MRSA agent.
You may also be interested in...
New potential topical therapy in dermatitis space set to move towards Japan approval submission based on positive new results.
Japan approval for BTK inhibitor marks new indication but in a small niche market, while another clearance may help extend Latuda's commercial life.
Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.